Phase I Analysis of the Safety and Pharmacodynamics of the Novel Broad Spectrum Histone Deacetylase Inhibitor (HDACi) PCI-24781 in Relapsed and Refractory Lymphoma.Andrew M. Evens, Nancy L. Bartlett, Weiyun Z. Ai et al.|Blood|2009Cited by 8
Abstract LB054: Confirmation of target inhibition and anti-tumor activity of the SHP2 inhibitor RMC-4630 via longitudinal analysis of ctDNA in a phase 1 clinical studyJosie Hayes, Eric B. Haura, Judy S. Wang et al.|Cancer Research|2021Cited by 4
Abstract LB050: Modulation of innate and adaptive immunity in blood and tumor of patients receiving the SHP2 inhibitor RMC-4630Ariel Yung-Chia Chen, Pasi A. Jänne, Eric B. Haura et al.|Cancer Research|2021Cited by 3